[
1. World Health Organization. World Mental Health Day DEPRESSION: A Global Crisis. 2012.
]Search in Google Scholar
[
2. Donohue MR, Luby J. Depression. The Curated Reference Collection in Neuroscience and Biobehavioral Psychology. Elsevier Science Ltd. 2016:366–73.
]Search in Google Scholar
[
3. Smith K. Mental health: a world of depression. Natur. 2014;515:181.10.1038/515180a
]Search in Google Scholar
[
4. Hagen EH. Evolutionary theories of depression: A critical review. Can J Psychiatry. 2011;56:716–26.10.1177/070674371105601203
]Search in Google Scholar
[
5. Peng G, Tian J, Gao X, Zhou Y, Qin X. Research on the pathological mechanism and drug treatment mechanism of depression. Curr Neuropharmacol. 2015;13(4):514–23.10.2174/1570159X1304150831120428
]Search in Google Scholar
[
6. Maes M, Yirmyia R, Noraberg J, Brene S, Hibbeln J, Perini G, et al. The inflammatory & neurodegenerative (I&ND) hypothesis of depression: Leads for future research and new drug developments in depression. Metab Brain Dis. 2009;24:27–53.10.1007/s11011-008-9118-1
]Search in Google Scholar
[
7. Evans DL, Charney DS, Lewis L, Golden RN, Gorman JM, Krishnan KRR, et al. Mood disorders in the medically ill: Scientific review and recommendations. Biol Psychiatry. 2005;58:175–89.10.1016/j.biopsych.2005.05.001
]Search in Google Scholar
[
8. Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology. 1999;38(8):1083–152.10.1016/S0028-3908(99)00010-6
]Search in Google Scholar
[
9. Berger M, Gray JA, Roth BL. The Expanded Biology of Serotonin. Annu Rev Med. 2009;60(1):355–66.10.1146/annurev.med.60.042307.110802586429319630576
]Search in Google Scholar
[
10. Goluch-Koniuszy Z, Fugiel J. Rola składników diety w syntezie wybranych neurotransmiterów. KOSMOS. 2016;65(4):523–34.
]Search in Google Scholar
[
11. Kazula A. Mechanizmy działania selektywnych inhibitorów wychwytu zwrotnego serotoniny (SSRI) w depresji. Farm Pol. 2014; 70(12):711–24.
]Search in Google Scholar
[
12. Nutt DJ, Baldwin DS, Clayton AH, Elgie R, Lecrubier Y, Montejo AL, et al. The role of dopamine and norepinephrine in depression and antidepressant treatment. J Clin Psychiatry. 2006;67: 46–9.
]Search in Google Scholar
[
13. Aggarwal S, Mortensen O V. Overview of monoamine transporters. Curr Protoc Pharmacol. 2017;79:12.16.1–12.16.17.10.1002/cpph.32584147329261228
]Search in Google Scholar
[
14. Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007;151(6):737–48.10.1038/sj.bjp.0707253201412017471183
]Search in Google Scholar
[
15. Strawn JR, Geracioti L, Rajdev N, Clemenza K, Levine A. Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review. Expert Opin Pharmacother. 2018;19(10):1057–70.10.1080/14656566.2018.1491966634039530056792
]Search in Google Scholar
[
16. Blier P, El-Mansari M. Serotonin and beyond: Therapeutics for major depression. Philos Trans R Soc Lond B Biol Sci. 2013;368(1615): 20120536.10.1098/rstb.2012.0536
]Search in Google Scholar
[
17. Jeleń A, Sałagacka A, Ballcerczak E. Charakterystyka wybranych mechanizmów molekularnych wpływających na farmakokinetykę i farmakodynamikę leków przeciwdepresyjnych. Postep Hig Med Dosw. 2015;69:753–62.10.5604/17322693.1160610
]Search in Google Scholar
[
18. De Monte C, D’Ascenzio M, Guglielmi P, Mancini V, Carradori S. Opening New Scenarios for Human MAO Inhibitors. Cent Nerv Syst Agents Med Chem. 2016;16(2):98–104.10.2174/1871524915666150831141705
]Search in Google Scholar
[
19. Youdim MB, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nat Revi Neurosci. 2006;7(4):295–309.10.1038/nrn1883
]Search in Google Scholar
[
20. Carradori S, Petzer JP. Novel monoamine oxidase inhibitors: A patent review. Expert Opin Ther Pat. 2015;25(1):91–110.10.1517/13543776.2014.982535
]Search in Google Scholar
[
21. Jarema M, Dudek D, Landowski J, Heitzman J, Rabe-Jabłońska J, Rybakowski J. Trazodon-lek przeciwdepresyjny: mechanizm działania i miejsce w leczeniu depresji. Psychiatr Pol. 2011;45(4): 611–25.
]Search in Google Scholar
[
22. Horst WD, Preskorn SH. Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. J Affect Disord. 1998;51(3):237–54.10.1016/S0165-0327(98)00222-5
]Search in Google Scholar
[
23. DeVane CL, Grothe DR, Smith SL. Pharmacology of antidepressants: focus on nefazodone. J Clin Psychiatry. 2002;63(1):10–7.
]Search in Google Scholar
[
24. Basgioura k i E, Papazisis G, Apostolidis A, Goulas A. Pharmacodynamic and pharmacokinetic properties of the novel antidepressant vortioxetine. Aristotle Univ Med J. 2016;43(3).
]Search in Google Scholar
[
25. Wang S-M, Han C, Lee S-J, Patkar AA, Masand PS, Pae C-U. Vilazodone for the Treatment of Depression: An Update. Chonnam Med J. 2016;52(2):91.10.4068/cmj.2016.52.2.91488058427231672
]Search in Google Scholar
[
26. Wysokiński A, Kłoszewska I. Wilazodon – nowy wielofunkcyjny lek przeciwdepresyjny. Psychiatria. 2013;10(2):72–5.
]Search in Google Scholar
[
27. Croom KF, Perry CM, Plosker GL. Mirtazapine: A review of its use in major depression and other psychiatric disorders. CNS Drug. 2009;23(5):427–52.10.2165/00023210-200923050-0000619453203
]Search in Google Scholar
[
28. Zupancic M, Guilleminault C. Agomelatine: A preliminary review of a new antidepressant. CNS Drugs. 2006;20(12):981–92.10.2165/00023210-200620120-0000317140278
]Search in Google Scholar
[
29. Anttila S, Leinonen E. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001;7(3):249–64.10.1111/j.1527-3458.2001.tb00198.x649414111607047
]Search in Google Scholar
[
30. Brogden R, Heel R, Speight T, Avery G. Mianserin: a review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs. 1978;16(4):273–301.10.2165/00003495-197816040-00001359311
]Search in Google Scholar
[
31. Quera-Salva M-A, Lemoine P, Guilleminault C. Impact of the novel antidepressant agomelatine on disturbed sleep–wake cycles in depressed patients. Hum Psychopharmacol Clin Exp. 2010;25(3):222–9.10.1002/hup.111220373473
]Search in Google Scholar
[
32. Prymus A, Krzystanek M, Bednarska-Półtorak K, Krupka-Matuszczyk I. Agomelatine – new possibility in treatment of affective disorders and sleep disorders. Probl Med Rodz. 2009;11(1).
]Search in Google Scholar
[
33. Roberts RJ, Lohano KK, El-Mallakh RS. Antipsychotics as antidepressants. Asia Pac Psychiatry. 2016;8(3):179–88.10.1111/appy.1218625963405
]Search in Google Scholar
[
34. Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry. 1999;60(4):256–9.10.4088/JCP.v60n0410
]Search in Google Scholar
[
35. Meltzer HY. Update on typical and atypical antipsychotic drugs. Annu Rev Med. 2013;64(1):393–406.10.1146/annurev-med-050911-16150423020880
]Search in Google Scholar
[
36. Suttajit S, Srisurapanont M, Maneeton N, Maneeton B. Quetiapine for acute bipolar depression: A systematic review and meta-analysis. Drug Des Devel Ther. 2014;8:827–38.10.2147/DDDT.S63779407739025028535
]Search in Google Scholar
[
37. Wasik A, Koałczkowski M, Wesoołwska A. Lurasidon - Nowy atypowy neuroleptyk o właściwościach przeciwdepresyjnych. Psychiatria. 2014;11(1):1–8.
]Search in Google Scholar
[
38. Permoda-Osip A, Rybakowski J. Koncepcja glutaminergiczna chorób afektywnych. Glutamatergic conception of mood disorders. Psychiatr Pol. 2011;45(6):875–88.
]Search in Google Scholar
[
39. Tokarski K, Kusek M, Sowa J, Bobula B. Receptory 5-HT7 a patofizjologia chorób afektywnych i działanie leków przeciwdepresyjnych. Postepy Hig Med Dosw. 2014;68:1104–13.10.5604/17322693.112092925228519
]Search in Google Scholar
[
40. Dziugieł R. Ketamina w walce z depresją, czyli stary anestetyk w nowej odsłonie. Probl Nauk Med i Nauk o Zdrowiu. 2019;10:25–32.
]Search in Google Scholar
[
41. Tibensky BN, de Léséleuc L, Perras C, Picheca L. Esketamine for Treatment-Resistant Depression. CADTH Issues in Emerging Health Technologies. 2016;176
]Search in Google Scholar
[
42. Kaur U, Pathak BK, Singh A, Chakrabarti SS. Esketamine: a glimmer of hope in treatment-resistant depression. Eur Arch Psychiatry Clin Neurosci. 201910.1007/s00406-019-01084-z31745646
]Search in Google Scholar
[
43. Palazidou E. The neurobiology of depression. Br Med Bull. 2012; 101:127–4510.1093/bmb/lds00422334281
]Search in Google Scholar
[
44. Wagstaff AJ, Ormrod D, Spencer CM. Tianeptine: A review of its use in depressive disorders. CNS Drug. 2001;15(3):231–59.10.2165/00023210-200115030-0000611463130
]Search in Google Scholar
[
45. Brink CB, Harvey BH, Brand L. Tianeptine: a novel atypical antidepressant that may provide new insights into the biomolecular basis of depression. Recent pat CNS Drug Discov. 2006;1:29–41.10.2174/15748890677524532718221189
]Search in Google Scholar
[
46. Alamo C, García-Garcia P, Lopez-Muñoz F, Zaragozá C. Tianeptine, an atypical pharmacological approach to depression. Rev Psiquiatr y Salud Ment. 2019;12(3):170–86.10.1016/j.rpsm.2018.09.00230612921
]Search in Google Scholar
[
47. McEwen BS, Chattarji S, Diamond DM, Jay TM, Reagan LP, Svenningsson P, et al. The neurobiological properties of tianeptine (Stablon): From monoamine hypothesis to glutamatergic modulation. Mol Psychiatr. 2010;15(3):237–49.10.1038/mp.2009.80290220019704408
]Search in Google Scholar
[
48. Madison CA, Eitan S. Buprenorphine: Prospective novel therapy for depression and PTSD. Psychol Med. 2020;50(6):881–93.10.1017/S003329172000052532204739
]Search in Google Scholar
[
49. Lutz PE, Kieffer BL. Opioid receptors: Distinct roles in mood disorders. TINS. 2013;36(3):195–206.
]Search in Google Scholar
[
50. Bodkin JA, Zornberg GL, Lukas SE, Cole JO. Buprenorphine treatment of refractory depression. J Clin Psychopharmacol. 1995;15(1):49–57.10.1097/00004714-199502000-000087714228
]Search in Google Scholar
[
51. Karp J, Butters M, Begley A, Miller M, Lenze E, Blumberger D, et al. Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults. J Clin Psychiatry. 2014;75(8):e785–93.10.4088/JCP.13m08725415731725191915
]Search in Google Scholar
[
52. Yovell Y, Bar G, Mashiah M, Baruch Y, Briskman I, Asherov J, et al. Ultra-low-dose buprenorphine as a time-limited treatment for severe suicidal ideation: A randomized controlled trial. Am J Psychiatry. 2016;173(5):491–8.10.1176/appi.ajp.2015.1504053526684923
]Search in Google Scholar
[
53. Stoll A, Rueter S. Treatment augmentation with opiates in severe and refractory major depression. Am J Psychiatr. 1999;156(12):2017.
]Search in Google Scholar
[
54. Serafini G, Adavastro G, Canepa G, De Berardis D, Valchera A, Pompili M, et al. The efficacy of buprenorphine in major depression, treatment-resistant depression and suicidal behavior: A systematic review. Int J Mol Sci. 2018:19(8).10.3390/ijms19082410612150330111745
]Search in Google Scholar
[
55. Toll L, Bruchas MR, Calo’ G, Cox BM, Zaveri NT. Nociceptin/orphanin FQ receptor structure, signaling, ligands, functions, and interactions with opioid systems. Pharmacol Rev. 2016;68(2):419–57.10.1124/pr.114.009209481342726956246
]Search in Google Scholar
[
56. Rorick-Kehn LM, Witkin JM, Statnick MA, Eberle EL, McKinzie JH, Kahl SD, et al. LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. Neuropharmacol. 2014;77:131–44.10.1016/j.neuropharm.2013.09.02124071566
]Search in Google Scholar
[
57. Broom DC, Jutkiewicz EM, Folk JE, Traynor JR, Rice KC, Woods JH. Convulsant activity of a non-peptidic δ-opioid receptor agonist is not required for its antidepressant-like effects in Sprague-Dawley rats. Psychopharmacol. 2002;164(1):42–8.10.1007/s00213-002-1179-y
]Search in Google Scholar
[
58. Broom DC, Jutkiewicz EM, Folk JE, Traynor JR, Rice KC, Woods JH. Nonpeptidic δ-opioid receptor agonists reduce immobility in the forced swim assay in rats. Neuropsychopharmacol. 2002;26(6):744–55.10.1016/S0893-133X(01)00413-4
]Search in Google Scholar
[
59. Dripps IJ, Jutkiewicz EM. Delta opioid receptors and modulation of mood and emotion. Handb Exp Pharmacol. 2018;247:179–97.
]Search in Google Scholar
[
60. Crippa JA, Guimarães FS, Campos AC, Zuardi AW. Translational investigation of the therapeutic potential of cannabidiol (CBD): Toward a new age. Front Immunol. 2018;9:2009.10.3389/fimmu.2018.02009616164430298064
]Search in Google Scholar
[
61. Schier A, Ribeiro N, Coutinho D, Machado S, Arias-Carrion O, Crippa J, et al. Antidepressant-like and anxiolytic-like effects of cannabidiol: A chemical compound of cannabis sativa. CNS Neurol Disord Drug Targets. 2014;13(6):953–60.10.2174/187152731366614061211483824923339
]Search in Google Scholar
[
62. Dulava SC, Janowsky DS. Cholinergic regulation of mood: From basic and clinical studies to emerging therapeutics. Mol Psychiatry. 2019;24(5):694–709.10.1038/s41380-018-0219-x719231530120418
]Search in Google Scholar
[
63. Adzic M, Brkic Z, Mitic M, Francija E, Jovicic MJ, Radulovic J, et al. Therapeutic strategies for treatment of inflammation-related depression. Curr Neuropharmacol. 2018;16(2):176–209.10.2174/1570159X15666170828163048588337928847294
]Search in Google Scholar
[
64. World Health Organization. Depression and Other Common Mental Disorders: Global Health Estimates. Geneva; 2017.
]Search in Google Scholar
[
65. Ionescu DF, Papakostas GI. Experimental medication treatment approaches for depression. Transl Psychiatry. 2017;7(3):e1068.10.1038/tp.2017.33541667628323287
]Search in Google Scholar
[
66. Won E, Kang J, Choi S, Kim A, Han KM, Yoon HK, et al. The association between substance P and white matter integrity in medication-naive patients with major depressive disorder. Sci Rep. 2017;7:9707.10.1038/s41598-017-10100-y557535028852030
]Search in Google Scholar